Free Trial
→ Collect $7k per month from Tesla’s SECRET dividend (From Investors Alley) (Ad)

CalciMedica Q1 2023 Earnings Report

CalciMedica logo
$2.35 -0.09 (-3.69%)
As of 02/21/2025 03:58 PM Eastern
Earnings HistoryForecast

CalciMedica EPS Results

Actual EPS
-$23.43
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CalciMedica Announcement Details

Quarter
Q1 2023
Date
5/12/2023
Time
N/A

Conference Call Resources

CalciMedica Earnings Headlines

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference
February 19 at 7:00 AM | prnewswire.com
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 3, 2025 | prnewswire.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors
January 14, 2025 | prnewswire.com
LUCID CAPITAL MARKETS Initiates Coverage of CalciMedica (CALC) with Buy Recommendation
December 18, 2024 | msn.com
Comprehensive 2024 Insights into the Acute Pancreatitis Pipeline Treatment Landscape Featuring CalciMedica, SCM Lifescience, and Lamassu Pharma
November 27, 2024 | finance.yahoo.com
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC), a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

View CalciMedica Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles